论文部分内容阅读
这是一项溴隐亭治疗帕金森病远期疗效的全国10a多中心前瞻性研究。6例单用溴隐亭持续治疗10a。22例应用溴隐亭加左旋多巴(在研究过程中加上的)使疾病得到了很好的控制。单用溴隐亭的6例10a间的病情则保持在Hoehn和Yahr的第Ⅰ期或第Ⅱ期,应用溴隐亭加左旋多巴治疗的其它22例疾病进展很慢已达7～8a。保持单用溴隐亭的6例没有1例发生过不良反应如食欲减退、动作困难或开-关现象。研究过程中,在开始应用左旋多巴治疗的22例中,
This is a nationwide multicenter prospective study of long-term efficacy of bromocriptine in the treatment of Parkinson’s disease. 6 cases of bromocriptine alone continued treatment 10a. 22 cases of bromocriptine plus levodopa (added during the study) made the disease well controlled. Only 6 cases of bromocriptine in the 10 cases of the disease remained in the Hoehn and Yahr stage Ⅰ or Ⅱ, the application of bromocriptine and levodopa treatment of the other 22 cases of progress has been slow to reach 7 ~ 8a. Six patients who remained single bromocriptine had no adverse reactions such as anorexia, dyskinesia or on-off behavior in none of the patients. In the study, of the 22 patients who started treatment with levodopa,